Pathological findings in central nervous system demyelination associated with infliximab.
Mult Scler
; 26(9): 1124-1129, 2020 08.
Article
em En
| MEDLINE
| ID: mdl-31845616
ABSTRACT
BACKGROUND:
Tumor necrosis factor alpha (TNF-alpha) inhibitors, such as infliximab, are commonly used to treat rheumatoid arthritis (RA) and other immune-mediated disorders.OBJECTIVE:
To determine whether infliximab-associated central nervous system (CNS) demyelination can be differentiated from multiple sclerosis (MS).METHODS:
We present a case of pathologically proven CNS demyelination in a patient treated with infliximab and describe clinical-radiographic-neuropathological findings. Putative mechanisms of TNF-alpha inhibitor-associated CNS demyelination are described. RESULTS ANDCONCLUSION:
Infliximab treatment is associated with CNS inflammatory demyelinating activity, which is histopathologically indistinguishable from MS.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Artrite Reumatoide
/
Antirreumáticos
/
Diabetes Mellitus Tipo 2
/
Esclerose Múltipla
Tipo de estudo:
Diagnostic_studies
/
Risk_factors_studies
Limite:
Aged
/
Humans
/
Male
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article